| Literature DB >> 32075822 |
Munire Tuxun1, Qian Zhao1,2,3, Yang Xiang1, Fen Liu1,2,3, Chun-Fang Shan1, Xin-Rong Zhou1,2, Ning Song1, Ajiguli Waisiding1, Xue-He Zhang1, Gulandanmu Aihemaiti1, Yi-Ning Yang4,2,3, Xiao-Mei Li4,2,3.
Abstract
OBJECTIVES: A combined equation based on white cell count (WCC) and total bilirubin (TB) was assessed for its ability to predict adverse clinical outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention (PCI).Entities:
Keywords: coronary heart disease; ischaemic heart disease; myocardial infarction
Mesh:
Substances:
Year: 2020 PMID: 32075822 PMCID: PMC7044918 DOI: 10.1136/bmjopen-2019-031227
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1The flowchart of study design with including and excluding procedures. K-M, Kaplan-Meier; MACE, major adverse cardiovascular event; ROC, receiver operating characteristic; STEMI, ST-segment elevation myocardial infarction.
Comparison between mace group and non-MACE group
| Variables | Non-MACE | MACE | T/χ2 | P value |
| Gender (men) (n,%) | 465 (86.4) | 63 (81.8) | 1.180 | 0.277 |
| Age (years)* | 57.8±12.2 | 61.2±11.8 | 2.359 | 0.019 |
| BMI (kg/m2) | 25.45±3.29 | 24.99±2.90 | 1.161 | 0.246 |
| Smoking history (n,%) | 302 (56.1) | 47 (61.0) | 0.660 | 0.416 |
| Hypertension (n,%) | 264 (49.1) | 40 (51.9) | 0.223 | 0.637 |
| Diabetes (n,%) | 115 (21.4) | 13 (16.9) | 0.825 | 0.364 |
| Hyperlipaemia (n,%) | 396 (73.6) | 61 (79.2) | 1.112 | 0.292 |
| SBP (mmHg) | 121.88±19.08 | 118.75±18.45 | 1.348 | 0.178 |
| DBP (mmHg) | 76.58±13.13 | 75.18±13.33 | 0.870 | 0.385 |
| Heart rate (/min) | 81.76±13.64 | 84.69±17.93 | 1.686 | 0.092 |
| LVEF (%)* | 58.52±6.58 | 55.48±7.82 | 3.703 | <0.001 |
| TB (μmol/L)* | 13.34±4.91 | 17.21±6.49 | 5.040 | <0.001 |
| DBL (μmol/L) | 2.19±1.60 | 2.18±1.41 | 0.100 | 0.920 |
| IBL (μmol/L) | 11.97±5.11 | 11.36±4.77 | 0.986 | 0.325 |
| TC (mmol/L) | 4.4±1.18 | 4.38±1.18 | 0.193 | 0.847 |
| TG (mmol/L) | 2.05±1.40 | 1.93±1.33 | 0.734 | 0.463 |
| LDL (mmol/L) | 2.86±0.85 | 2.8±0.84 | 0.544 | 0.587 |
| HDL (mmol/L) | 1.03±0.35 | 1.03±0.31 | 0.004 | 0.997 |
| CK-MB (U/L) | 277.73±221 | 306.14±204.18 | 1.065 | 0.287 |
| WCC (×109/ L)* | 10.31±2.85 | 13.01±4.11 | 5.569 | <0.001 |
| Hb (g/L) | 145.24±19.96 | 142.47±23.72 | 1.114 | 0.266 |
| PLT (×109/ L) | 222.25±59.41 | 221.6±66.85 | 0.089 | 0.929 |
| UC (mmol/L)* | 5.27±1.70 | 6.67±2.40 | 4.921 | <0.001 |
| CR (μmol/L)* | 75.46±18.79 | 83.95±24.38 | 2.934 | 0.004 |
| GRACE | 133 (115~148) | 136 (116~158) | 1.250 | 0.211 |
| LM (n,%) | 51 (9.5) | 4 (5.2) | 1.519 | 0.218 |
| LAD (n,%) | 463 (86.1) | 71 (92.2) | 2.227 | 0.136 |
| LCX (n,%) | 334 (62.1) | 53 (68.8) | 1.315 | 0.251 |
| RAD (n,%) | 372 (69.1) | 61 (79.2) | 3.282 | 0.070 |
| Culprit Vessels* | 2.80±1.27 | 3.21±1.25 | 2.631 | 0.009 |
| TIMI grade post-PCI* | 3 (1~3) | 2 (1~3) | 2.567 | 0.023 |
| Medication | ||||
| Aspirin | 519 (96.5) | 73 (94.8) | 0.518 | 0.472 |
| Clopidogrel* | 498 (92.6) | 64 (83.1) | 7.635 | 0.006 |
| β blockers | 441 (82.0) | 62 (80.5) | 0.095 | 0.758 |
| ACEI | 382 (71.0) | 55 (71.4) | 0.006 | 0.939 |
| Statins* | 505 (93.9) | 66 (85.7) | 6.739 | 0.009 |
*P<0.05
ACEI, angiotensin-converting enzyme inhibitor; BMI, body mass index; CKMB, creatine kinase isoenzymes; CR, creatinine; DBL, direct bilirubin; DBP, diastolic blood pressure; GRACE, globla registry of acute coronary events; Hb, haemoglobin; HDL-C, high-density lipoprotein cholesterol; IBL, indirect bilirubin; LAD, left anterior descending branch; LCX, left circumflex branch; LDL-C, low-density lipoprotein cholesterol; LM, left main coronary artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; PLT, platelet; RAD, right coronary descending branch; SBP, systolic blood pressure; TB, total bilirubin; TC, total cholesterol; TG, triglycerides; TIMI, thrombolysis in myocardial infarction; UC, uric acid; WCC, white cell count.
The combined equation of logistic regression of in-hospital mortality
| Variables | B | OR | 95% CI | P value |
| TB | 0.077 | 1.080 | −0.005 to 0.159 | 0.067 |
| WCC | 0.265 | 1.303 | 0.125 to 0.405 | <0.001 |
| Constant term | −8.004 | 0.002 | <0.001 |
TB, total bilirubin; WCC, white cell count.
Admission of TB, WCC and combine as predictors of in-hospital mortality
| Variables | Sensitivity (%) | Specificity | AUC | 95% CI | C-statistic | P value |
| TB (≥14.4 mmol/L) | 76.5 | 62.0 | 0.751 | 0.660 to 0.842 | 7.989 | 0.032 |
| WCC (≥12.2×109/L) | 71.0 | 73.1 | 0.765 | 0.625 to 0.904 | ||
| Combine (≥1.4) | 82.4 | 64.7 | 0.804 | 0.678 to 0.928 | ||
| hs-TnT (≥0.87 µg/mL) | 85.2 | 77.8 | 0.894 | 0.831 to 0.961 |
AUC, area under the curve; hs-TnT, hypersensitive troponin; TB, total bilirubin; WCC, white cell count.
Figure 2Admission of TB, WCC and combine as predictors of in-hospital mortality. TB, total bilirubin; WCC, white cell count.
Univariate and multivariate logistic analysis of in-hospital mace
| Variables | Univariate | Multivariate | ||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Gender (male) | 1.69 (0.763 to 3.767) | 0.195 | ||
| Age (year) | 1.02 (1.003 to 1.055) | 0.025 | 1.03 (1.002 to 1.049) | 0.028 |
| BMI | 0.98 (0.896 to 1.072) | 0.660 | ||
| Smoking | 1.71 (0.933 to 3.141) | 0.083 | ||
| Hypoglycaemic | 0.87 (0.506 to 1.494) | 0.614 | ||
| Diabetes | 0.77 (0.3841.542) | 0.460 | ||
| Heart rate | 1.01 (0.993 to 1.027) | 0.249 | ||
| LVEF | 0.96 (0.926 to 0.990) | 0.011 | 0.96 (0.928 to 0.990) | 0.010 |
| LDL-C | 0.88 (0.640 to 1.205) | 0.422 | ||
| CK-MB | 1.00 (0.999 to 1.001) | 0.166 | ||
| Culprit vessels | 1.29 (1.045 to 1.601) | 0.018 | 1.25 (1.019 to 1.529) | 0.032 |
| Combine (cut-off=1.4) | 5.55 (3.207 to 9.609) | 0.000 | 5.85 (3.425 to 9.990) | <0.001 |
BMI, body mass index; CK-MB, creatine kinase isoenzymes; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction.
Figure 3Kaplan-Meier survival analysis of long-term mace. MACE, major adverse cardiovascular event.